Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a press release. The approval, for patients whose cancer is positive for homologous recombination deficiency (HRD), is based on data from the PAOLA-1 Phase 3 trial (NCT02477644), in which oral Lynparza significantly extended the time patients lived without disease worsening by about 1.5 years. Similar approvals have…
You must be logged in to read/download the full post.
The post Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers appeared first on BioNewsFeeds.